Charles River Laboratories International, Inc. CRL

Charles River Laboratories International, Inc. es una empresa de investigación por contrato de servicio completo en etapas tempranas. La empresa proporciona productos y servicios para ayudar a empresas farmacéuticas, biotecnológicas, agencias gubernamentales e instituciones académicas en la investigación y desarrollo de medicamentos. La empresa opera a través de dos segmentos: Descubrimiento y Evaluación de Seguridad (DSA) y Soluciones de Manufactura (Manufacturing). El segmento DSA incluye servicios necesarios para llevar un medicamento a través del proceso de desarrollo temprano, incluidos servicios de descubrimiento, que son servicios no regulados para ayudar a los clientes con la identificación, selección y selección de un compuesto líder para el desarrollo de medicamentos, y servicios de evaluación de seguridad regulados y no regulados (Buenas Prácticas de Laboratorio (BPL) y no BPL). El segmento de Manufactura incluye Soluciones Microbianas, Soluciones Biológicas y Servicios de Vacunas Aviares.

• GlobeNewswire Inc. 5 oct

  Cell and Gene Therapy Biomanufacturing Market - Size, Share, and Forecast, 2026-2031 | Automation, Viral Vectors, and CDMO Expansion Drive 11.7% CAGR to $8.7 Billion

  The global cell and gene therapy biomanufacturing market is projected to grow from $5.0 billion in 2026 to $8.7 billion by 2031, driven by an 11.7% CAGR. Growth is fueled by increasing regulatory approvals, rising demand for scalable manufacturing infrastructure, and investments in automation and modular systems. However, high production costs, regulatory complexity, and workforce shortages remain significant challenges.

  

• Zacks Investment Research 30 sept

  Is Aveanna Healthcare (AVAH) Stock Outpacing Its Medical Peers This Year?

  Aveanna Healthcare (AVAH) has significantly outperformed the Medical sector year-to-date, returning 56.4% compared to the sector's 2.8% average return. The company holds a Zacks Rank #2 (Buy) with consensus earnings estimates up 23.2% in the past quarter, indicating improved analyst sentiment. Charles River Laboratories (CRL) is another Medical stock outperforming with a 48.4% year-to-date return.

  

• GlobeNewswire Inc. 29 sept

  Pharmaceutical Impurity Synthesis and Isolation Services Report: Capitalize on a $2.1 Billion Market by 2030 as Tariffs and 8.9% Isolation Growth Reshape Competition Across Eurofins, WuXi AppTec, Cambrex and Charles River

  The global pharmaceutical impurity synthesis and isolation services market is projected to grow from $1.3 billion in 2024 to $2.1 billion by 2030 at a 7.7% CAGR. Growth is driven by stricter regulatory requirements, increasing drug complexity, biologics expansion, and rising pharmaceutical outsourcing. Isolation services are expected to grow fastest at 8.9% CAGR, while analytical services will advance at 5.7% CAGR.

  

• GlobeNewswire Inc. 21 sept

  Rare Disease Contract Research Organization (CRO) Market Outlook 2026-2030: Investment Trends, Strategic Profiles and Revenue Share Outlook

  The global rare disease CRO market is projected to grow from $2.07 billion in 2025 to $3.16 billion by 2030, with an 8.9% CAGR. Growth is driven by expanding gene and cell therapy pipelines, increasing orphan drug approvals, precision medicine adoption, and decentralized clinical trials. Key trends include AI integration, patient registries, and real-world evidence utilization.

  

• Zacks Investment Research 18 sept

  PGNY vs. CRL: Which Stock Is the Better Value Option?

  A comparison of two Medical Services sector stocks, Progyny (PGNY) and Charles River Laboratories (CRL), both with Zacks Rank #2 (Buy). Based on valuation metrics including forward P/E ratio (12.92 vs 24.87), PEG ratio (1.12 vs 2.76), and Value grades (B vs D), Progyny is identified as the superior value opportunity.